Concord Medical Reports Second Quarter 2012 Financial Results

Updates Guidance for Full Year 2012 Revenues

BEIJING, Aug. 20, 2012 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today reported its unaudited consolidated financial results for the second quarter ended June 30, 2012[1].

Second Quarter 2012 Highlights

  • Total net revenues in the second quarter of 2012 were RMB136.5 million ($21.5 million), a 10.2% increase from the second quarter of 2011.  "Lease and management services"revenues in the second quarter of 2012 were RMB119.5 million ($18.8 million), a 15.3% increase from the second quarter of 2011.
  • Gross profit in the second quarter of 2012 was RMB93.9 million ($14.8 million), a 12.1% increase from the second quarter of 2011.
  • Gross profit margin in the second quarter was 68.7%, compared to 58.4% in the first quarter of 2012 and 67.6% in the second quarter of 2011.
  • Net income in the second quarter of 2012 was RMB38.3 million ($6.0 million), a 2.3% increase from the second quarter of 2011. Both basic anddiluted earnings per American depositary share ("ADS")[2] for the second quarter of 2012 were RMB0.80 ($0.13).
  • Non-GAAP net income[3] in the second quarter of 2012 was RMB40.6 million ($6.4 million), a 2.4% increase from the second quarter of 2011. Both non-GAAP basic and diluted earnings per ADS for the second quarter of 2012 were RMB0.85 ($0.13).
  • Adjusted EBITDA[4](non-GAAP) in the second quarter of 2012 was RMB93.7 million ($14.7 million), a 10.0% increase from the second quarter of 2011, representing an EBITDA margin of 68.6% in the second quarter of 2012 compared to 68.8% in the second quarter of 2011.
  • Five new centers were established and two centers were closed in the second quarter of 2012, bringing the total number of centers in operation to 133 in 52 cities across 24 provinces in China as of June 30, 2012. The Company had outstanding agreements to establish 36 new centers, as of June 30, 2012.
  • The numbers of treatment and diagnostic patient cases in the second quarter of 2012 were 8,820 and 52,833, respectively, representing a 2.5% and 25.7% increase from the second quarter of 2011.

1 This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.353 to US$1.00, the effective noon buying rate as of June 29, 2012 in the City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York.

 

2 Each ADS represents three ordinary shares of the Company.

 

3 Non-GAAP net income is defined in this announcement as net income excluding share-based compensation. Share-based compensation was RMB2.2 million and RMB 2.3 million ($0.4 million) in the second quarter 2011 and 2012, respectively.

 

4 Adjusted EBITDA is defined in this  announcement as net income plus interestexpense, income tax expenses, depreciation and amortization, share-based compensation expenses, and other adjustments, including foreign exchange gains or losses, other income, and gain from disposal of property, plant and equipment.

"In the second quarter of 2012, we delivered healthy growth and increased net revenues compared with the second quarter of 2011," said Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, "Our core lease and management services business experienced strong growth momentum, benefiting from the expanding social insurance program in China.  We are confident in our expansion strategy and growth prospects. We are pushing forward on all fronts to establish standalone hospitals, open new centers with hospital partners, pursue acquisition targets, and increase the utilization rate andoperational efficiency at our existing facilities."

Recent Developments

Update on Chang'an Hospital Acquisition – On June 18, Concord Medical announced thesuccessful closing of its acquisition of 52% equity interests in Chang'an Hospital, a leading non-public general hospital located in Xi'an, Shaanxi Province. Previously, the company announced the signing of a definite agreement in connection with the acquisition on March 22, 2012.  Since then, the Company has received all necessary government approvals including a New Business License for Chang'an Hospital, and it has completed all registration procedures, including Capital Verification Report, Share Ownership Report, and Business Registration Change Report. During the first half of 2012, Chang'an Hospital generated revenues (unaudited) of RMB185.5 million, a 57.8% increase over the first half of 2011. The financial results of Chang'an Hospital will be reflected in the consolidated financial statements of the Company in the third quarter.

Update on the Guangzhou Joint Venture Project with Sun Yat-Sen University Cancer Center -- The Company has obtained the approval from the Ministry of Health of Guangdong Province to build a 400-bed specialty cancer hospital. The Company expects to break ground on this project in early 2013.

Share repurchase program -- During the second quarter of 2012, the Company repurchased 394,169 ADSs, representing 1,182,507 ordinary shares, for an aggregate consideration of $1.4 million (including commissions), under the share repurchase program approved by the board of directors of the Company on September 30, 2011. Since the inception of the program, the Company has repurchased 1,283,847 ADSs, representing 3,851,541 ordinary shares, for an aggregate consideration of $4.6 million (including commissions).

Second quarter 2012 Results

Total net revenues were RMB136.5 million ($21.5 million)  in the second quarter of 2012, a 10.2% increase from the second quarter of 2011, primarily due to the increases in the number of patient cases and centers in operation compared with the second quarter of 2011.

Cost of revenues in the second quarter of 2012 was RMB42.7 million ($6.7 million), a 6.4% increase from the second quarter of 2011, primarily due to an increase in depreciation costs related to new equipment, partially offset by lower consumable and other center-related expenses as a result of our cost-control measures.

Gross profit margin in the second quarter of 2012 was 68.7%, as compared to 67.6% in the second quarter of 2011. The higher gross profit margin is a result of cost-control measures taking effect as well as revenue contribution from recently-opened centers which have passed their ramp-up phases.

Operating expenses, consisting of selling, general and administrative expenses, were RMB37.0 million ($5.8 million) in the second quarter of 2012 as compared to RMB28.6 million in the second quarter of 2011.  Selling expenses were RMB10.4 million ($1.6 million) in the second quarter of 2012, representing 7.6% of the total net revenues as compared to 9.0% in the second quarter of 2011.  The decrease as a percentage of net revenues was mainly due to the cost control measures implemented since the beginning of 2012.General and administrative expenses were RMB26.6 million ($4.2 million) in the second quarter of 2012, representing 19.5% of the total net revenues as compared to 14.1% in the second quarter of 2011.  The increaseas a percentage of net revenues was mainly due to an increase in rental expenses as well as other headquarter-related expenses.

Operating income was RMB56.8 million ($8.9 million) in the second quarter of 2012, a 3.1% increase from the second quarter of 2011. Operating income excluding share-based compensation expenses (non-GAAP) was RMB59.1 million ($9.3 million), a 3.1% increase from the second quarter of 2011.

Income tax expenses in the second quarter of 2012 were RMB16.9 million ($2.7 million), compared to an income tax expense of RMB14.0 million in the second quarter of 2011. The effective tax rate for the second quarter of 2012 was 30.7% as compared to 27.2% in the second quarter of 2011.

Net income in the second quarter of 2012 was RMB38.3 million ($6.0 million), a 2.3% increase from the second quarter of 2011. Both basic and diluted earnings per ADS for the second quarter of 2012 were RMB0.80 ($0.13), as compared to RMB0.79 in the second quarter of 2011.

Non-GAAP net income in the second quarter of 2012 was RMB40.6 million ($6.4 million), a 2.4% increase from the second quarter of 2011. Both non-GAAP basic and diluted earnings per ADS in the second quarter of 2012 were RMB0.85 ($0.13) compared to RMB0.84 in the second quarter of 2011.

Adjusted EBITDA (non-GAAP) was RMB93.7 million ($14.7 million) for the second quarter of 2012, representing a 10.0% increase from the second quarter of 2011, primarily due to increase in operating income and depreciation expenses during the period.

Capital expenditure in the second quarter of 2012 was RMB51.6 million ($8.1 million), primarily on purchasing new equipment for new centers.

As of June 30, 2012, the Company had total fixed assets of RMB1, 087.4 million ($171.2 million), cash of RMB130.7 million ($20.6 million), and restricted cash of RMB69.9 million ($11.0 million).

As of June 30, 2012, the Company had bank credit lines of RMB765.0 million ($120.4 million), of which RMB274.9 million ($43.3 million) were drawn down.

Accounts receivable was RMB250.4 million ($39.4 million) as of June 30, 2012, as compared to RMB244.2 million as of December 31, 2011.

Days sales outstanding was approximately 159 days in the second quarter of 2012, substantially less than 201 days in the first quarter of 2012, as a result of strengthened collection measures since the beginning of the year.

2012 Outlook

The Company intends to provide consolidated financial results that include the results of Chang'an Hospital beginning with the third quarter of 2012. The Company also updated its guidance for the second half of 2012 fiscal year as follows:

  • Net revenues from the current network business of RMB220 million to RMB240 million ; and
  • Revenues from Chang'an Hospital of RMB190 million to RMB210 million, reflecting six months of financial results; and
  • Network capital expenditures of RMB80 million to RMB120 million, primarily on purchasing new equipment for new centers.

Conference Call Information

Concord Medical's management will hold an earnings conference call at 8:00 a.m. EDT on August 21, 2012 (8:00 p.m. Beijing/Hong Kong time on August 21, 2012).

Dial-in details for the earnings conference call are as follows:

U.S. Toll Free: 1-866-519-4004
International: 1-718-354-1231
U.K. Toll Free: 8082346646
China Toll Free: 400-620-8038 / 800-819-0121
Hong Kong Toll Free: 800-930-346
Passcode: CCM

A replay of the conference call may be accessed by phone at the following number until August 28, 2012:

U.S. Toll Free: 1-866-214-5335
International: 1-718-354-1232
Passcode: 18045582

Additionally, a live and archived webcast of this conference call will be available at http://ir.concordmedical.com/.

About Concord Medical

Concord Medical Services Holdings Limited operates the largest network of radiotherapy and diagnostic imaging centers in China, measured by revenues and the number of centers in operation. As of June 30, 2012, the Company operated a network of 133 centers with 75 hospital partners that spanned 52 cities and 24 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, Concord Medical provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.concordmedical.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, many of the statements from management in this press release and the section under "Outlook for Full Year 2012" are forward-looking in nature.  These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance.  Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; and technological or therapeutic changes affecting the field of cancer treatment and diagnostic imaging.  Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles (GAAP), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expense. The Company believes excluding share-based compensation expense from its non-GAAP financial measures is useful for its management and investors to assess and analyze the Company's core operating results as such expense is not directly attributable to the underlying performance of the Company's business operations and do not impact its cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expense are important in helping investors to understand the Company's current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of Adjusted EBITDA, which is defined in this announcement as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange losses and other income, and loss from disposal of property, plant and equipment. Furthermore, Adjusted EBITDA eliminates the impact of items that the Company does not consider indicative of the performance of its network of centers. The Company believes investors will similarly use Adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.

For more information, please contact:

Concord Medical Services
Mr. Tony Tian
[email protected]
(+86) 10 5957-5287

Solebury Communications
In China:
Ms. Ran Zhang
[email protected]
(+86) 10 6563-0288

In the United States:
Mr. Richard Zubek
[email protected]
(+1) 203-428-3230

Concord Medical Services Holdings Co., Ltd. 

Unaudited Condensed Consolidated Balance Sheets

(in thousands)

 


December 31, 2011 (*)

             June 30, 2012            


RMB

RMB

US$





ASSETS




Current assets




Cash 

219,078

130,729

20,578

Restricted cash, current portion

2,512

39,312

6,188

Held-to-maturity securities

100,466

-

-

Time deposit with original maturities exceeding three months

50,372

-

-

Accounts receivable

244,189

250,383

39,412

Prepayments and other current assets

61,630

72,133

11,354

Net investments in direct financing leases, current portion

49,821

74,305

11,696

Deferred tax assets, current portion

5,589

5,064

797

Total current assets

733,657

571,926

90,025





Non-current assets




Property, plant and equipment, net

1,068,703

1,087,444

171,170

Acquired intangible assets, net

129,018

117,254

18,456

Deposits for non-current assets

207,287

185,910

29,263

Prepayment for acquisition of Chang'an

-

248,909

39,180

Net investments in direct financing leases, non-current portion

97,262

138,834

21,853

Deferred tax assets, non-current portion

20,866

18,956

2,984

Equity method investments

540

540

85

Other non-current assets

86,731

84,392

13,284

Restricted cash, non-current portion

22,012

30,601

4,817

Prepaid land lease payments

27,370

26,998

4,250

Total non-current assets

1,659,789

1,939,838

305,342





Total assets

2,393,446

2,511,764

395,367









LIABILITIES AND EQUITY




Current liabilities




Short-term bank borrowings

15,000

15,000

2,361

Long-term bank borrowings, current portion

77,479

92,156

14,505

Accounts payable

2,170

452

71

Accrual for purchase of property, plant and equipment

13,294

11,229

1,768

Obligations under capital leases, current portion

3,582

3,582

564

Accrued expenses and other liabilities

59,097

59,241

9,325

Income tax payable

20,936

23,265

3,662

Deferred revenue, current portion

13,115

12,955

2,039

Contingent business acquisition consideration 

11,999

11,999

1,889

Total current liabilities

216,672

229,879

36,184





Non-current liabilities




Long-term bank borrowings, non-current portion

108,700

172,760

27,193

Deferred revenue, non-current portion

6,839

4,197

661

Obligations under capitalized leases, non-current portion

2,289

653

103

Lease deposits

2,000

2,000

315

Deferred tax liabilities, non-current portion

18,850

18,284

2,878

Total non-current liabilities

138,678

197,894

31,150





Total liabilities

355,350

427,773

67,334





Commitments and contingencies








EQUITY




Ordinary shares

105

105

17

Treasuary stock

(1)

(3)

-

Additional paid-in capital

2,551,877

2,534,273

398,909

Accumulated other comprehensive loss

(17,595)

(17,383)

(2,736)

Accumulated deficit

(599,886)

(538,493)

(84,762)

Total Concord Medical Services Holdings Limited 

shareholders' equity

1,934,500

1,978,499

311,428

Non-controlling interests

103,596

105,492

16,605





Total equity

2,038,096

2,083,991

328,033





Total liabilities and equity 

2,393,446

2,511,764

395,367





(*) Amounts for the year ended December 31, 2011 were derived from the December 31, 2011 audited consolidated financial statements.

 

Concord Medical Services Holdings Limited

Unaudited Condensed Consolidated Statements of Income

(in thousands, except per  ADS data)

 


For The Three Months Ended


June 30, 2011 (*)

June 30, 2012


RMB

RMB

US$

Revenue, net of business tax, value-added tax and related surcharges




Lease and management services

103,650

119,542

18,817

Management services

11,784

4,071

641

Other, net

8,413

12,917

2,033

Total net revenues

123,847

136,530

21,491





Cost of revenues




Depreciation

(20,657)

(27,319)

(4,300)

Amortisation of acquired intangibles

(6,463)

(6,303)

(992)

Others

(12,998)

(9,053)

(1,425)

Total cost of revenues

(40,118)

(42,675)

(6,717)





Gross profit

83,729

93,855

14,774





Operating expenses








Selling expenses

(11,144)

(10,426)

(1,641)

General and administrative expenses

(17,424)

(26,580)

(4,184)





Operating income

55,161

56,849

8,949

Interest expenses

(1,661)

(3,504)

(552)

Foreign exchange (loss) gain

(3,108)

399

63

Gain from disposal of property, plant and equipment

-

92

14

Interest income

1,052

1,367

215

Other income

-

33

5





Income before income taxes

51,444

55,236

8,694

Income tax expenses

(14,015)

(16,933)

(2,665)

Net income

37,429

38,303

6,029





Net income attributable to noncontrolling interests

1,495

1,087

171





Net income attributable to ordinary shareholders

35,934

37,216

5,858





Earnings per ADS




Basic /Diluted

0.79

0.80

0.13





Weighted average number of ADS outstanding:




Basic /Diluted

47,451,177

46,359,145

46,359,145





Other comprehensive (loss) income, net of tax




Foreign currency translation

(1,206)

184

29

Total other comprehensive (loss) income, net of tax

(1,206)

184

29





Comprehensive income

36,223

38,487

6,058





(*) Certain amounts in the prior year quarterly financial information are being reclassified for comparison purposes.

 

Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures (*) (in RMB thousands, unaudited)









For the three months ended June 30, 2011

For the three months ended June 30, 2012


GAAP Result

Adjustment

Non-GAAP Results

GAAP Result

Adjustment

Non-GAAP Results

Operating income

55,161

2,200

57,361

56,849

2,282

59,131

Net income

37,429

2,200

39,629

38,303

2,282

40,585

Basic earnings per ADS

0.79

0.05

0.84

0.80

0.05

0.85

Diluted earnings per ADS

0.79

0.05

0.84

0.80

0.05

0.85








(*) The only adjustment is share-based compensation.

 

Reconciliation from net income to adjusted EBITDA(*) (in RMB thousands, unaudited)








For the three months ended

For the three months ended


June 30, 2011

June 30, 2012

Net income

37,429

38,303

   Interest expenses (income), net

609

2,137

   Income tax expenses

14,015

16,933

   Depreciation and amortization

27,858

34,568

   Share-based compensation

2,200

2,282

   Other adjustments

3,108

(524)




Adjusted EBITDA

85,219

93,699




(*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange losses, gain from disposal of property, plant and equipment and other income.
 

SOURCE Concord Medical Services Holdings Limited

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.